From an article in last year's JAMA [Jl of the Amer Med Assoc]: (via Jack)
Results.... Compared with placebo, cannabinoids were associated with a greater average number of patients showing a complete nausea and vomiting response ..., reduction in pain ..., a greater average reduction in numerical rating scale pain assessment ..., and average reduction in the Ashworth spasticity scale... . There was an increased risk of short-term AEs [adverse events] with cannabinoids, including serious AEs. Common AEs included dizziness, dry mouth, nausea, fatigue, somnolence, euphoria, vomiting, disorientation, drowsiness, confusion, loss of balance, and hallucination.
Conclusions and RelevanceThere was moderate-quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity. There was low-quality evidence suggesting that cannabinoids were associated with improvements in nausea and vomiting due to chemotherapy, weight gain in HIV infection, sleep disorders, and Tourette syndrome. Cannabinoids were associated with an increased risk of short-term AEs.
It's time to let consumers decide whether they want to try marijuana to treat some of the symptoms.